CureVac Salute del bilancio
Salute finanziaria criteri di controllo 4/6
CureVac has a total shareholder equity of €376.5M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €556.8M and €180.3M respectively.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
€0
Debito
Indice di copertura degli interessi | n/a |
Contanti | €202.52m |
Patrimonio netto | €376.53m |
Totale passività | €180.30m |
Totale attività | €556.84m |
Aggiornamenti recenti sulla salute finanziaria
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Recent updates
CureVac: Back To Square One
Oct 08CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
Sep 16CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02Analisi della posizione finanziaria
Passività a breve termine: CVAC's short term assets (€251.6M) exceed its short term liabilities (€110.0M).
Passività a lungo termine: CVAC's short term assets (€251.6M) exceed its long term liabilities (€70.3M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CVAC is debt free.
Riduzione del debito: CVAC currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: CVAC has less than a year of cash runway based on its current free cash flow.
Previsione Cash Runway: Insufficient data to determine if CVAC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.